Argenx shares rise 7.2% after disappointing study of competitor Biohaven's proteolytic drug — traders
在竞争对手Biohaven的蛋白质降解剂药物令人失望的研究之后Argenx股价上涨了7.2％——交易者
Argenx shares rise 7.2% after disappointing study of competitor Biohaven's proteolytic drug — traders
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.